We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.30 | 1.20 | 1.40 | 1.30 | 1.30 | 1.30 | 333,263 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.71 | 1.76M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/8/2020 07:55 | TRX still under the Radar. | hodhasharon | |
23/8/2020 22:02 | Yes, block, aka, stick your fingers in your ears, and go 'la la la la I can't hear you'. Do you realise when you block someone it doesn't work the other way around. We can still see your posts. But if it makes you feel more secure, in your confirmation bias echo chamber safe space, pull the blankets over your head and do it 😂 | davevt | |
23/8/2020 21:45 | They add 0 value Hod, just block them. | spudyoulike | |
23/8/2020 19:13 | “What's funny is they say it should be worth 100p, with absolutely zero basis.” ....and the basis offered for a 4p valuation is..... Bloody newbies... | hodhasharon | |
23/8/2020 19:09 | It's funny reading the posts on lse....'201k buy, people are taking positions!' Yes dude, that's a bad thing, not a good thing. You have someone now wanting to SELL 201k shares when news comes out. Sells make the price go down or saturate buys, not up 😂 Buys and volume only matter when news comes out, otherwise, it's a bad thing. | davevt | |
23/8/2020 18:28 | What's funny is they say it should be worth 100p, with absolutely zero basis. May as well say 1000p, it makes no difference. 'We will be trading at 120p by the end of the year'....funny, the rampers have been saying that for the last 3 years. And here it is, back down in single digits like it always does. | davevt | |
23/8/2020 18:00 | Nothing is certain in this business save to say you will come across Some dipstick rampers/parasites like shoddy and stig.theyknow they have been rumbled but cannot help themselves,hence their Sunday night ramps.100p/200p this year the men in white coats must be knocking on their doors soon. | albert3591 | |
23/8/2020 16:49 | Very much looking forward to news from VAL201 as a PYC shareholder Can see it being transformational news www.proactiveinvesto | the stigologist | |
23/8/2020 15:25 | PYC is a certain multi-bagger. We’ll be trading at the 100-120p range by the end of the year. | hodhasharon | |
23/8/2020 11:47 | It is Sunday perhaps they could call on Devine intervention.LOL | albert3591 | |
23/8/2020 11:41 | Oh spuds on the ramp too now, talking about things years away, that could well never happen, and would just pay the debt they were owed from ten years ago. This is the thing, even if it happened, rampers would be like 'oh they got the licencing deal'.....but it's not 'extra' money, it's money they have been owed for TEN YEARS 😂 | davevt | |
23/8/2020 11:39 | Cancer AI 'leaders'? 😂😂 OK Stig, just stop. Seriously, I don't think there is any company below pyc. Honestly. | davevt | |
23/8/2020 11:16 | If they haven’t cottoned on they will never do,not worth bothering with in the first place,unless your a parasite ramper that is. | albert3591 | |
22/8/2020 20:59 | HUGE news i missed on Friday AstraZeneca partner with £400m (zero revenue) RENX on Kidney AI How long before big players cotton on to UK cancer AI leaders Physiomics | the stigologist | |
22/8/2020 20:57 | With VAL due to release results for l&ll clinical trials for VAL201 in the coming weeks, it's worth taking a look at the pre-licensing upfront averages. PYC take a % cut on any deals for work carried out in Pre-clinical trials 10 yrs ago. Globaldata - 2011/2016Big pharma. - ph 1 av £61 million Ph 2 av £125 millionAll Licensors - ph 1 av £45 million Ph 2 av £62 million | spudyoulike | |
22/8/2020 08:09 | So Simulations Plus (Mkt Cap $1bn) have raised $115m for 'strategic M&A' That is some war-chest. Even if they don't come knocking for Physiomics (Mkt Cap £7.5m) I expect this continuing Industry M&A to lift valuations across the sector For Immediate Release: August 10, 2020 Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares LANCASTER, CA, August 10, 2020 – Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, today announced the closing of its previously announced underwritten public offering of 2,090,909 shares of its common stock to the public at $55.00 per share, which included the full exercise of the underwriters’ option to purchase 272,727 additional shares of common stock. The aggregate gross proceeds to Simulations Plus from this offering were approximately $115 million, before deducting underwriting discounts and commissions and other offering expenses payable by Simulations Plus. | the stigologist | |
21/8/2020 16:00 | I feel hurt now, looks like the redline got breeched oh dear me. | albert3591 | |
21/8/2020 15:18 | This board looks so much cleaner after blocking Dave and Albert. | spudyoulike | |
21/8/2020 15:06 | Author: Riddler (LSE) Here are the facts! Sheephatch and new investors: Market cap £6mln and 98mln shares 70% compound revenue growth 2017-19 Last update June 2020 Cash £1.25mln (raised £850k May 2020) + £150k grant May 2020 98million shares in issue Record revenues last 3yrs and therefore £790k for 2019 (1/7th of market cap) Signed significant new major client in July 2020 ,Japanese multi national More deals expected H2 2020 Jim Millen (CEO ) Joined in 2016 with 15yrs experience across blue chip globals and smaller UK companies. Previously had a Business Development role at GlaxoWhat do they do?Physiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs."With another record year behind us, we continue our journey to becoming a sustainably profitable business. In the next twelve months we're aiming to execute more projects than ever before and to add further new clients both in the UK, Europe and North America. We expect and indeed welcome a balance between larger and small clients and target a further diversification "2019 developmentsMay 17th ICR announces £75mln for a new UK centre for Artificial intelligence use in cancer research of which PYC will be part of judging by the fact PYC tweeted the article and ICR work with PYC.June 28th Signs contract with NASDAQ listed and $200mln valued Bicycle GroupJuly 8thSigns a deal with CancerResearch UK and Bicycle group for their lead compound which has $30mln -40mln committed spend for Phase II/ III trialsS"analysis of clinical data arising from the ongoing Cancer Research UK-sponsored Phase I/IIa clinical trial of Bicycle Therapeutics' lead program, BT1718, in solid tumours"December 2019 Another renewal with Merck ( whom are working on a $4.2bln+programmme with Glaxo) A new contract with Cellcentric A new TR1 holder who appears to be connected to Merck and Glaxo via previous roles whom added to go above 4.5% in April 20202020 developments May 2020 26th May , results and £850k placing with a deal with a new major pharmacy client due to be signed imminently Z .Ali Goes to 5%+ in May 2020 and adds 800k more in the 26th May placing £150k Innovate Grant for Prostate cancer May 2020June 2020 Confirms another new contract with Bicycle and late stages of signing the major client. July 2020 signs deal with a large Japanese multi nationalAugust 2020 confirms via an official tweet that is working with C19 drug developments with other partners QSP is increasingly used in drugdevelopment to guide research & accelerate the discovery process. At Physiomics, we work with pharma biotech clients to create integrated QSP models & rigorously test them to provide valuable insights. | spudyoulike | |
21/8/2020 13:23 | Keep doing the red ones shoddy. | albert3591 | |
21/8/2020 13:08 | Maybe he meant decanting? He is into cheap asda wine after all. | davevt |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions